A new study suggests that natalizumab (Tysabri, Biogen Idec/Elan) may be an effective option for the treatment of active paediatric multiple sclerosis (MS).
The study, a cohort study of 35 pediatric patients treated out to 23 months with natalizumab, showed that the drug was safe and well-tolerated and was effective in suppressing disease activity in almost all patients.
"I think the message is that the pediatric patient is no different in their response," to natalizumab than adult patients, senior author Giancarlo Comi, MD, director of the Department of Neurology and Institute of Experimental Neurology at the Scientific Institute and University Vita-Salute San Raffaele in Milan, Italy, told Medscape Medical News. "So there is absolutely no reason not to treat paediatric patients."... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1408